Current status on microRNAs as biomarkers for ovarian cancer
- PMID: 26809719
- DOI: 10.1111/apm.12514
Current status on microRNAs as biomarkers for ovarian cancer
Abstract
Ovarian cancer (OC) is the most lethal gynecological malignancy in the Western world, and has a very poor prognosis, often due to late diagnosis and emergence of chemotherapy resistance. Therefore, there is an essential need for new diagnostic and prognostic markers that can improve and initiate more personalized treatment, eventually improving survival of the patients. MicroRNAs are small, non-coding RNA molecules, that post-transcriptionally regulate gene expression. Several studies have within the last decade shown that microRNAs are deregulated in OC and have potential as diagnostic and prognostic biomarkers for OC. Recently studies have also focused on microRNAs as predictors of chemotherapy responses and their potential as therapeutic targets. However, many of the published studies are difficult to interpret as a whole due to various methods of analysis. Future focus should be aimed at developing a general standardized analytical method, which can limit differences between studies thus allowing easier comparison across them. In addition, validation of studies in independent series that ideally should be histotype-specific is essential to determine the clinical role of microRNAs in different types of OC. In this review we summarize the current knowledge of microRNAs as potential biomarkers for OC, with focus on their clinical relevance.
Keywords: MicroRNA; biomarkers; ovarian cancer.
© 2016 APMIS. Published by John Wiley & Sons Ltd.
Similar articles
-
Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.Expert Opin Biol Ther. 2017 Aug;17(8):927-943. doi: 10.1080/14712598.2017.1340935. Epub 2017 Jun 22. Expert Opin Biol Ther. 2017. PMID: 28641048 Review.
-
Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.Biomed Pharmacother. 2016 Dec;84:592-600. doi: 10.1016/j.biopha.2016.09.087. Epub 2016 Sep 30. Biomed Pharmacother. 2016. PMID: 27694003 Review.
-
MicroRNAs as prognostic markers in ovarian cancer.Mol Cell Endocrinol. 2014 Jun 5;390(1-2):73-84. doi: 10.1016/j.mce.2014.03.006. Epub 2014 Apr 18. Mol Cell Endocrinol. 2014. PMID: 24747602 Review.
-
microRNA and Ovarian Cancer.Adv Exp Med Biol. 2015;889:119-51. doi: 10.1007/978-3-319-23730-5_8. Adv Exp Med Biol. 2015. PMID: 26659000 Review.
-
MicroRNAs in Ovarian Cancer.Hum Pathol. 2015 Sep;46(9):1245-56. doi: 10.1016/j.humpath.2015.06.013. Epub 2015 Jun 30. Hum Pathol. 2015. PMID: 26216350 Review.
Cited by
-
Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.PLoS One. 2019 Nov 18;14(11):e0225249. doi: 10.1371/journal.pone.0225249. eCollection 2019. PLoS One. 2019. PMID: 31738788 Free PMC article.
-
Tumor Markers and Their Diagnostic Significance in Ovarian Cancer.Life (Basel). 2023 Aug 5;13(8):1689. doi: 10.3390/life13081689. Life (Basel). 2023. PMID: 37629546 Free PMC article. Review.
-
Metabolic pathways of potential miRNA biomarkers derived from liquid biopsy in epithelial ovarian cancer.Oncol Lett. 2023 Feb 23;25(4):142. doi: 10.3892/ol.2023.13728. eCollection 2023 Apr. Oncol Lett. 2023. PMID: 36909377 Free PMC article.
-
Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.PLoS One. 2018 Nov 26;13(11):e0207319. doi: 10.1371/journal.pone.0207319. eCollection 2018. PLoS One. 2018. PMID: 30475821 Free PMC article.
-
Involvement of non-coding RNAs in chemotherapy resistance of ovarian cancer.J Cancer. 2018 Apr 30;9(11):1966-1972. doi: 10.7150/jca.24550. eCollection 2018. J Cancer. 2018. PMID: 29896281 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical